Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary intervention

Experimental and Clinical Cardiology

Volumn 15, Issue 3, 2010, Pages

  Germing, Alfried ^a   Bojara, Waldemar ^a   Lawo, Thomas ^a   Ewers, Aydan ^a   Grewe, Peter ^a   Mügge, Andreas ^a   Lindstaedt, Michael ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Bleeding complications; Glycoprotein IIb IIIa inhibitors; Octogenarians; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; HEPARIN; THIENOPYRIDINE DERIVATIVE; THROMBIN; TIROFIBAN; WARFARIN;

AGED; ARTICLE; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; COMPRESSION THERAPY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FALSE ANEURYSM; FEMALE; FEMORAL ARTERY; FEMORAL HEMATOMA; FEMORAL PSEUDOANEURYSM; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY;

EID: 78049241084     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol 2007;23:963-70. (Pubitemid 47629125)
2. Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999;138:S287-S296. (Pubitemid 29471022)
3. Madan M, Blankenship JC, Berkowitz SD. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Curr Opin Hematol 1999;6:334-41.
4. Mak KH, Effron MB, Moliterno DJ. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Drugs Aging 2000;16:179-87.
5. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995;91:2882-90.
6. EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk patients. N Engl J Med 1994;330:956-61.
7. Ali A, Hashem M, Rosman HS, et al. Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: A single-center experience in 1020 patients. J Clin Pharmacol 2004;44:1328-32.
8. Assali AR, Moustapha A, Sdringola S, et al. The dilemma of success: Percutaneous coronary interventions in patients > or = 75 years of age - successful but associated with higher vascular complications and cardiac mortality. Catheter Cardiovasc Interv 2003;59:195-9.
9. Bossi I, Piccaluga E, Scatturin M, et al. Percutaneous coronary interventions in elderly patients: Clinical indications and adjunctive medical treatment. The Italian Drug Evaluation in Angioplasty (IDEA) study. G Ital Cardiol 2006;7:136-44.
10. Guagliumi G, Stone GW, Cox DA, et al. Outcome in elderly patients undergoing primary intervention for acute myocardial infarction: Results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2004;110:1598-604.
11. Huynh T, Piazza N, DiBattiste PM, et al. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: Insights from the PRISM-PLUS study. Int J Cardiol 2005;100:73-8.
12. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-5.
13. Konstance R, Tcheng JE, Wightman MB, et al. Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. J Interv Cardiol 2004;17:65-70. (Pubitemid 38648471)
14. Lenderink T, Boersma E, Ruzyllo W, et al. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. Am Heart J 2004;147:865-73.
15. Piper WD, Malenka DJ, Ryan TJ Jr, et al. Predicting vascular complications in percutaneous coronary interventions. Am Heart J 2003;145:1022-9.
16. Hovanesyan A, Rich W. Outcomes of acute myocardial infarction in nonagenarians. Am J Cardiol 2008;101:1379-83.
17. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-35.
18. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
19. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
20. IMPACT II-Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997;349:1422-8.
21. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
22. PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
23. Casterella PJ, Revenaugh JR, Burke JL, et al. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. J Invasive Cardiol 2008;20:94-8.
24. Fransson SG, Nylander E. Vascular injury following cardiac catheterization, coronary angiography, and coronary angioplasty. Eur Heart J 1994;15:232-5. (Pubitemid 24110701)
25. Mathis AS, Gugger JJ. Percutaneous coronary intervention-related bleeding risk factors in current practice. Ann Pharmacother 2005;39:1627-33.
26. Pinkau T, Ndrepepa G, Kastrati A, et al. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. Cardiology 2008;111:247-53.